-
Company Insights
Credit Suisse Private Banking – Competitor Profile
Credit Suisse Private Banking Competitor Profile Overview Headquartered in Zurich, Switzerland Credit Suisse is a global bank that provides private banking, wealth management, corporate banking, investment banking, and retail banking services to individuals, corporations, and institutions in around 50 countries. The Credit Suisse Private Banking competitor profile report comprehensively analyzes Credit Suisse Private Banking's private banking operations. It offers insights into the company’s strategy and financial performance, including key data on AUM. Customer targeting and service propositions are covered, as...
-
Sector Analysis
Lewy Body Dementia (LBD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Lewy Body Dementia Pipeline Drug Analysis Report Overview Lewy body dementia (LBD) is a common type of dementia that happens when clumps of proteins called Lewy bodies build up in the brain. They damage parts of the brain that affect cognition, behavior, movement, and sleep. Lewy body intracellular inclusions result from the aggregation of misfolded α-synuclein. There will be more than 1.1 million diagnosed prevalent cases of LBD in 2023 in the 16 countries covered in GlobalData’s epidemiology forecast for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – neflamapimod
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry neflamapimod Drug Details Neflamapimod (VX-745) is under development for the treatment of Alzheimer's disease,...
-
Product Insights
Stroke Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Stroke can occur with symptoms including sudden numbness in their face or limbs, particularly down one side of their body. The sufferer may appear confused and have trouble talking or understanding what is being said to them. They may have vision problems, and trouble walking or keeping their balance. The Stroke pipeline drugs market research report outlays comprehensive information on the Stroke targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA)...
-
Sector Analysis
Telco Digital Brand Leverage as Part of a Transformation Journey
Telco Digital Brand Report Overview The emergence of technologies such as big data analytics and artificial intelligence (AI) has allowed telcos to automate customer interactions. This significantly reduces the need for human interactions, helps in improving customer satisfaction, and contributes to significant operational cost savings. As telecom services become increasingly commoditized, providing an outstanding customer experience has become a key service differentiator. E-care apps and digital brands leverage the use of AI-led chatbots embedded in e-care apps, and operator websites...
-
Product Insights
Dementia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Dementia is the loss of mental functions such as thinking, memory, and reasoning that is severe enough to interfere with a person's daily functioning. Symptoms include memory loss, hallucinations, agitation, personality changes, and difficulty with coordination and motor functions. Risk factors include age, smoking, obesity, high blood pressure, inflammation, and cardiovascular diseases. The Dementia Drugs in Development market research report provides an overview of the Dementia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dementia,...
-
Product Insights
Alzheimer’s Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Alzheimer’s Disease Drugs Development Report Overview Alzheimer's disease is a progressive, degenerative condition causing damage to memory and behavior due to the attack on the neurons. Predisposing factors include age, heredity, cardiovascular diseases or diabetes, and environmental factors. Symptoms include depression, anxiety, social withdrawal, irritability, and aggressiveness. Buy the Full Report for More Insights on the Alzheimer’s Disease Drugs in Development Report, Download a Free Sample The Alzheimer’s Disease Drugs in Development market research report provides an overview of the...
-
Analyst Opinions
Chilled Raw Packaged Meat – Whole Cuts Market in Australia to 2019
The report presents detailed data on consumption trends in the Chilled Raw Packaged Meat - Whole Cuts category in South Korea, analyzing consumption volumes and values at segment level. It also provides indispensable data on distribution channels along with latest industry news and mergers & acquisitions (of Meat market). Furthermore the report enables readers to examine the components of change in the industry by looking at historic and future growth patterns.
-
Analyst Opinions
Implications of Device Financing Plans and Lack of Handset Subsidies for Operator Profitability in Europe
Operator profitability in the mobile segment in Europe is under pressure, particularly in more mature markets where expensive handsets are often subsidized in order to drive growth in high ARPU postpaid segments. In retracting device subsidy offers, operators have the potential to ease this financial pressure and lower the cost per customer acquisition, as discussed in Section 1. Such strategic shifts can merit rewards but are never risk-free. Section 2 contains specific European case studies (Germany, Netherlands, the United Kingdom...
-
Thematic Analysis
Biomarkers in the Central Nervous System
Biomarkers in CNS are expected to be an area that will witness strong growth in the future due to factors such as deeper understanding of the underlying disease pathology, advancements in technologies, and potential of these biomarkers that can contribute to targeted therapy. Biomarkers in CNS targeting a number of neurology indications are being developed; however, the most common ones are Alzheimer’s disease (AD), Schizophrenia and Multiple Sclerosis (MS). This report provides an overview of current clinical and product development...